Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

The Swedish Drug Development Pipeline 2014

Reference number
Coordinator SwedenBIO Service AB
Funding from Vinnova SEK 100 000
Project duration December 2013 - November 2014
Status Completed

Purpose and goal

The goal was to collect information about the project portfolio of future drugs in Swedish biotech and pharmaceutical companies and visualize the state of the industry and the need for support. The aim was to gain insight of the project pipeline with focus in projects that have reached the clinic (Phase I-III). Both goal and aim has have successfully been meet.

Results and expected effects

A report was produced according to plan. The report was launched at SwedenBIO CEO Summit and in conjunction to that it attracted attention in the media.

Approach and implementation

Initially, research was done in order to identify Swedish pharmaceutical- and biotech companies developing new drugs. The companies were invited to fill in an online questionnaire with questions about their projects. About one hundred companies were identified. The survey was conducted during the second half of 2014 and were compiled during the autumn. The report was released at SwedenBIO CEO Summit. In conjunction with the release the report attracted attention in media e.g. Life Science Sweden, six nyhetsbyrå, Läkemedelsvärlden och Läkemedelsmarknaden.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 November 2019

Reference number 2013-05519

Page statistics